NeuroThera Labs Inc. Engages Dr. Reuter Investor Relations for European Market Expansion

Toronto, Ontario — August 27, 2026 — Leads & Copy — NeuroThera Labs Inc., a clinical-stage biotech company and a subsidiary of SciSparc Ltd., has engaged Dr. Reuter Investor Relations to provide investor awareness and communications services across Germany and the broader European capital markets, effective September 1, 2026. Dr. Reuter is a European investor relations and financial communications firm with an established network of institutional investors, retail shareholders, and financial media throughout the DACH region and the European Union.

The engagement aims to enhance NeuroThera's visibility among European investors, support market education regarding its clinical research strategy, and strengthen shareholder communications. Dr. Reuter's services will include campaign and editorial articles, translation and distribution of press releases, journalist targeting, social media outreach, and ongoing performance reporting. The agreement commences September 1, 2026, for an initial six-month term ending February 28, 2027, with a monthly fee of €6,000, payable in advance. Additionally, Dr. Reuter may provide services for an investor roadshow at an estimated cost of €12,900 per roadshow, payable in advance. NeuroThera expects to engage Dr. Reuter for one roadshow during the agreement term. Following the initial term, the agreement will continue on a month-to-month basis. Dr. Reuter is arm's length to NeuroThera, and to the Company's knowledge, holds no securities of NeuroThera.

NeuroThera Labs Inc. is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations. The company is a subsidiary of SciSparc Ltd.

Source: NeuroThera Labs Inc.